LEADS BIOLABS-B (09887) saw its share price increase by 7.91% in the morning session, currently trading at HKD 66.20, with a turnover of HKD 28.44 million.

On February 13, Hang Seng Indexes Company announced the quarterly review results for the Hang Seng Index Series up to December 31, 2025, in which LEADS BIOLABS was included in the Hang Seng Composite Index. The changes will be implemented after the market close on March 6, 2026, and take effect from March 9, 2026. At that time, the Shanghai and Shenzhen Stock Exchanges will correspondingly adjust the scope of investable targets under the Stock Connect program. According to a CICC research report, LEADS BIOLABS is likely to be added to the Stock Connect scheme, as it meets a series of criteria including market capitalization, liquidity, and listing time.

Recently, LEADS BIOLABS announced that the first patient has been successfully dosed in an open-label, multicenter Ib/II phase clinical study evaluating Velixin™ (the PD-L1/4-1BB bispecific antibody Opatisumab, LBL-024) for the treatment of recurrent or metastatic triple-negative breast cancer. The study, led by Professor Yin Yongmei from Jiangsu Provincial People's Hospital, is being conducted simultaneously at multiple hospitals across the country. The trial aims to evaluate the efficacy and safety of Opatisumab, both as a monotherapy and in combination with nab-paclitaxel, for patients with recurrent or metastatic triple-negative breast cancer.